Daily Cardiology Research Analysis
Today's top cardiology papers span mechanistic insight, causal-inference-driven comparative effectiveness, and human metabolic physiology. Single-nucleus RNA-seq delineates distinct immune signatures in myocarditis after SARS-CoV-2 infection versus vaccination. A large target trial emulation suggests advanced pulmonary recanalization strategies outperform VA-ECMO alone in high-risk PE, while invasive metabolic phenotyping links cardiac resynchronization therapy to acute substrate shifts that pre
Summary
Today's top cardiology papers span mechanistic insight, causal-inference-driven comparative effectiveness, and human metabolic physiology. Single-nucleus RNA-seq delineates distinct immune signatures in myocarditis after SARS-CoV-2 infection versus vaccination. A large target trial emulation suggests advanced pulmonary recanalization strategies outperform VA-ECMO alone in high-risk PE, while invasive metabolic phenotyping links cardiac resynchronization therapy to acute substrate shifts that predict reverse remodeling.
Research Themes
- Immune mechanisms in inflammatory cardiomyopathy
- Comparative effectiveness in high-risk pulmonary embolism
- Cardiac metabolic flexibility and remodeling after CRT
Selected Articles
1. The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after SARS-CoV-2 infection and COVID-19 vaccination.
Single-nucleus RNA-seq of human myocardial biopsies revealed etiology-specific immune programs in myocarditis. Post-COVID myocarditis featured interferon-γ–centric signatures, whereas post-vaccination myocarditis showed upregulated IL16 and IL18, with broadly similar myeloid responses but a higher CD4 compartment in post-vaccination cases.
Impact: Provides high-resolution mechanistic differentiation of myocarditis etiologies that may guide biomarker selection and targeted immunomodulation. The study advances understanding of vaccine-associated myocarditis without conflating it with post-infectious disease.
Clinical Implications: Cytokine signatures (IFN-γ vs IL16/IL18) could enable etiology-informed diagnostics and rationalize trials of pathway-specific therapies. Findings caution against assuming uniform immune targets across myocarditis phenotypes.
Key Findings
- Single-nucleus RNA-seq delineated distinct cytokine expression programs by etiology in human myocarditis.
- Post-COVID myocarditis showed interferon-γ–centric signatures.
- Post-vaccination myocarditis was marked by upregulated IL16 and IL18 and a higher proportion of CD4 cells, with broadly similar myeloid responses across groups.
Methodological Strengths
- Single-nucleus transcriptomics directly on human myocardial tissue across etiologies
- Comparative design enabling mechanistic differentiation between post-infection and post-vaccination myocarditis
Limitations
- Sample size and group sizes not specified in abstract; potential power limitations
- Cross-sectional tissue profiling cannot establish causality or temporal dynamics
Future Directions: Validate cytokine signatures in larger, prospective cohorts; assess circulating biomarkers correlating with tissue programs; explore targeted immunomodulation stratified by etiology.
Myocarditis, characterized by inflammatory cell infiltration, can have multiple etiologies, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or, rarely, mRNA-based coronavirus disease 2019 (COVID-19) vaccination. The underlying cellular and molecular mechanisms remain poorly understood. In this study, we performed single-nucleus RNA sequencing on left ventricular endomyocardial biopsies from patients with myocarditis unrelated to COVID-19 (Non-COVID-19), after SARS-CoV-2 infection (Post-COVID-19) and after COVID-19 vaccination (Post-Vaccination). We identified distinct cytokine expression patterns, with interferon-γ playing a key role in Post-COVID-19, and upregulated IL16 and IL18 expression serving as a hallmark of Post-Vaccination myocarditis. Although myeloid responses were similar across all groups, the Post-Vaccination group showed a higher proportion of CD4
2. Management of high-risk acute pulmonary embolism: an emulated target trial analysis.
In a target trial emulation of 991 high-risk PE patients, estimated in-hospital mortality was lower with systemic thrombolysis (48%), surgical thrombectomy (34%), or catheter-directed therapy (43%) compared with VA-ECMO alone (57%). Robust sensitivity analyses supported the benefit of advanced pulmonary recanalization strategies over VA-ECMO as sole support.
Impact: Addresses a critical evidence gap in management of high-risk PE using state-of-the-art causal inference across multiple advanced strategies, informing practice where RCTs are challenging.
Clinical Implications: When feasible, prioritize advanced pulmonary recanalization (systemic thrombolysis, surgical thrombectomy, or catheter-directed therapy) over VA-ECMO alone; ECMO may serve as a bridge in selected cases.
Key Findings
- Estimated in-hospital mortality: VA-ECMO alone 57% vs systemic thrombolysis 48%, surgical thrombectomy 34%, catheter-directed therapy 43%.
- Mortality risk ratios favored any recanalization strategy over VA-ECMO alone across sensitivity analyses (g-formula, TMLE, IPTW).
- Survivors had high likelihood of favorable neurologic outcomes across groups.
Methodological Strengths
- Target trial emulation with g-formula and multiple robust sensitivity analyses (TMLE, IPTW)
- Large multi-center cohort spanning four contemporary strategies with allowance for ECMO bridging
Limitations
- Observational design with potential residual confounding and selection bias
- Heterogeneity in institutional protocols and device availability; no randomized allocation
Future Directions: Prospective registries with standardized protocols; pragmatic trials where feasible; subgroup analyses to tailor therapy (e.g., clot burden, shock severity).
BACKGROUND: High-risk acute pulmonary embolism (PE) is a life-threatening condition necessitating hemodynamic stabilization and rapid restoration of pulmonary perfusion. In this context, evidence regarding the benefit of advanced circulatory support and pulmonary recanalization strategies is still limited. METHODS: In this observational study, we assessed data of 1060 patients treated for high-risk acute PE with 991 being included in a target trial emulation to investigate all-cause in-hospital mortality estimates with different advanced treatment strategies. The four treatment groups consisted of patients undergoing (I) veno-arterial extracorporeal membrane oxygenation (VA-ECMO) alone (n = 126), (II) intrahospital systemic thrombolysis (SYS) (n = 643), (III) surgical thrombectomy (ST) (n = 49), and (IV) percutaneous catheter-directed treatment (PCDT) (n = 173). VA-ECMO was allowed as bridging to pulmonary recanalization in groups II, III, and IV. Marginal causal contrasts were estimated using the g-formula with logistic regression models as the primary approach. Sensitivity analyses included targeted maximum likelihood estimation (TMLE) with machine learning, inverse probability of treatment weighting (IPTW), as well as variations of estimands, handling of missing values, and a complete target trial emulation excluding the VA-ECMO alone group. RESULTS: In the overall target trial population, the median age was 62.0 years, and 53.3% of patients were male. The estimated probability of in-hospital mortality from the primary target trial intention-to-treat analysis for VA-ECMO alone was 57% (95% confidence interval [CI] 47%; 67%), compared to 48% (95% CI 44%; 53%) for intrahospital SYS, 34% (95%CI 18%; 50%) for ST, and 43% (95% CI 35%; 51%) for PCDT. The mortality risk ratios were largely in favor of any advanced recanalization strategy over VA-ECMO alone. The robustness of these findings was supported by all sensitivity analyses. In the crude outcome analysis, patients surviving to discharge had a high probability of favorable neurologic outcome in all treatment groups. CONCLUSION: Advanced recanalization by means of SYS, ST, and several promising catheter-directed systems may have a positive impact on short-term survival of patients presenting with high-risk PE compared to the use of VA-ECMO alone as a bridge to recovery.
3. Metabolic flexibility and reverse remodelling of the failing human heart.
CRT acutely increased stroke work by 34–36% without increasing myocardial O2 uptake and shifted substrate metabolism toward greater fatty acid and ketone utilization. At 6 months, LV end-diastolic volume fell by 48%, and reverse remodeling correlated with acute increases in FA uptake (insulin/glucose infusion) and ketone uptake (intralipid).
Impact: Links human myocardial metabolic flexibility at the time of CRT to structural reverse remodeling using invasive physiology and omics, suggesting metabolic phenotyping as a predictor of CRT response.
Clinical Implications: Metabolic shifts toward fatty acid and ketone utilization during CRT may identify patients likely to remodel favorably and inform adjunctive metabolic strategies.
Key Findings
- CRT acutely increased stroke work by 34% (insulin/glucose) and 36% (intralipid) without increasing O2 uptake.
- Acute increases in fatty acid uptake (R = 0.89) and β-hydroxybutyrate uptake (R = 0.81) were observed under substrate infusions.
- At 6 months, LVEDV decreased by 48% and reverse remodeling correlated with increased FA uptake (R = 0.71) and ketone uptake (R = 0.79).
Methodological Strengths
- Direct coronary arteriovenous sampling with metabolomic/lipidomic profiling
- Integrated pressure-volume loops and serial cardiac MRI over 6 months
Limitations
- Sample size not reported in abstract; likely small mechanistic cohort limiting generalizability
- Borderline P-values and absence of randomized control group
Future Directions: Prospective validation of metabolic predictors of CRT response; test adjunct metabolic therapies to potentiate reverse remodeling.
BACKGROUND AND AIMS: Cardiac resynchronization therapy (CRT) produces long-term reverse remodelling which requires greater adenosine triphosphate delivery to the contractile machinery. Whilst the heart retains some metabolic flexibility in non-ischaemic cardiomyopathy, whether this correlates with reverse remodelling is unknown. This study investigated whether CRT acutely changes cardiac substrate uptake, and whether this translates to favourable reverse remodelling. METHODS: The effect of CRT on cardiac substrate uptake was assessed via direct coronary flow and arteriovenous measurements, with metabolomic/lipidomic analysis on infusions of insulin/glucose and intralipid. Cardiac function was assessed with left ventricular pressure-volume loops during implantation, and cardiac magnetic resonance before and 6 months following CRT, with and without biventricular pacing. RESULTS: Regardless of substrate infusion, CRT acutely improved stroke work without increasing O2 uptake on both insulin/glucose (by 34%, P = .05) and intralipid (by 36%, P = .03). This was followed by increased fatty acid (FA) uptake on insulin/glucose (R = 0.89, P = .03) and increased β-hydroxybutyrate uptake (R = 0.81, P = .05) during intralipid infusion. After 6 months, there was a 48% (P < .001) reduction in left ventricular end diastolic volume, beyond that achievable by acutely shortening or lengthening QRS duration. Reverse remodelling significantly correlated with increased FA uptake with CRT on insulin/glucose (R = 0.71, P = .05) driven by long and medium chain uptake, and increased ketone uptake with CRT on intralipid (R = 0.79, P = .05). CONCLUSIONS: CRT acutely alters the metabolic phenotype of non-ischaemic cardiomyopathy towards a more physiological picture of FA uptake which correlates with reverse remodelling. Retained metabolic flexibility may therefore be critical for subsequent reverse remodelling.